• PROTEOMICS AND GENOMICS

    from the same FFPE tissue

    learn more
  • MOLECULAR ANALYSIS THAT MAXIMIZES

    multiplex results from minimal tissue

    learn more
  • PATENTED LIQUID TISSUE TECHNOLOGY

    prepares both DNA & protein

    learn more

Precision medicine requires the accurate assessment of molecular alterations within a patient’s tumor.

NantOmics provides solutions that detect genomic and proteomic alterations in cancer giving healthcare providers individual molecular profiles for personalized of patient management.

What we provide
NantOmics employs a comprehensive, integrated panomic approach to detect molecular alterations in individual tumors and inform physicians about personalized treatment options for patients with cancer. Whole genome sequencing of a patient’s matched tumor sample and normal sample pinpoints tumor-specific alterations at the DNA level, quantitative proteomics measures the levels of clinically important proteins, and integrative analysis identifies disrupted pathways that are specific to the patient’s tumor.

OncoPlexDx® Targeted Proteomics
The OncoPlexDx Targeted Proteomic panel provides protein biomarker information for multiple clinically relevant proteins that are the targets for chemotherapy agents and targeted therapies.

NantSeq™ test 
The NantSeq test is a laboratory test that can identify genomic alterations in patient tumor samples and match those alterations to available therapies that may be active against tumors containing the specific alteration. For more information about the NantSeq test, click here.

Integrated analysis 
Our knowledge database, comprised of hundreds of oncogenes and thousands of cellular pathways, identifies genomic and proteomic alterations with the highest clinical relevance to each patient’s tumor. The alterations are then matched to targeted drugs that might be active against tumors containing the specific alteration.

The NantSeq report lists potential treatment options, if available. The report may list FDA-approved targeted drugs with potential for clinical benefit, active clinical trials of drugs with potential for clinical benefit, and/or available drugs to which the cancer may be resistant. The NantSeq report does not recommend a treatment plan, and it is the responsibility of the treating physician to develop a personalized treatment plan after discussing the available treatment options and the potential risks associated with each treatment option with the patient.

Contact us to learn more.